About Precision Prostate Consulting

customerservice@precisionprostateconsulting.com

A Provider of Prostate Cancer Second Opinions and Provider Consultations

Physicians: Register for an account and upload the study as detailed here – and we will offer you an AI-supported diagnostic report. (Patients click here)

Get an MRI

Doctors: Upload your patient's MRI scan to our system

We receive this information and return an AI-supported diagnostic report

Doctors: Use the following billing code:xxxx to get reimbursed from insurance.

ABOUT US

Our Story

Precision Prostate Consulting (PPC) was founded by seasoned experts within the Prostate healthcare space who are dedicated to establishing an entirely new standard of care (SOC) in the detection, diagnosis and treatment of prostate cancer. By bringing together the combined expertise of key opinion leaders in radiology, urology, medical imaging and artificial intelligence, PCC has significantly raised the bar in prostate cancer detection, diagnosis and treatment planning.

Precision Prostate Consulting’s AI-support second opinion consultation provides valuable insights and recommendations that aid in the early detection of prostate cancer. ProstatID® analyzes patient MRI and medical history data, leading to earlier diagnoses, enhanced treatment planning and improved outcomes.

PROSTATID

Our Technology

ProstatID is a radiological AI-powered detection (CADe) and diagnostic (CADx) software-only device for use in a healthcare facility or hospital to assist trained radiologists and clinical specialists in the detection, assessment and characterization of lesions suspicious for cancer based upon MRI image data. ProstatID automatically registers images, segments and analyzes the central gland and entire prostate. ProstatID identifies suspicious abnormalities by employing a pixel-wise, learning-based artificial intelligence methodology that has been trained against large MRI image sets with correlated histologic biopsy samples that serve as ground truth data.

FUTURE APPLICATIONS

Our Vision

At PPC, we are committed to employing non-contrast MRI – known as bi-parametric MRI (bpMRI) – for advanced screening of prostate cancer (PCa). A 15-20 MRI scan, augmented with AI-powered interpretation software by ProstatID) demonstrates 93.6% effectiveness* in contrast to the inferior results of digital rectal exams – which yield less than 60% effectiveness – and non-correlative Prostate Specific Antigen (PSA) blood test. A number peer-reviewed studies indicate the PSA blood test is not correlated to PCa; however, it does serve as an early warning signal of prostate abnormalities which indicate the need for further testing such as bpMRI plus AI. Our vision is that AI-augmented bpMRI is the new standard of care for screening of men over 55, or those with other indicators, such as family history of PCa or breast cancer.

*see resources: Area Under the ROC (sensitivity-specificity curve)

OUR EXPERTISE